| Autor: |
Hao S; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213., Tong J; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213., Jha A; UPMC Hillman Cancer Center, Pittsburgh, PA 15213., Risnik D; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213., Lizardo D; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213., Lu X; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213., Goel A; Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA 91010., Opresko PL; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.; Department of Environmental and Occupational Health, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213., Yu J; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213., Zhang L; UPMC Hillman Cancer Center, Pittsburgh, PA 15213.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213. |
| Abstrakt: |
Synthetic lethality is a powerful approach for targeting oncogenic drivers in cancer. Recent studies revealed that cancer cells with microsatellite instability (MSI) require Werner (WRN) helicase for survival; however, the underlying mechanism remains unclear. In this study, we found that WRN depletion strongly induced p53 and its downstream apoptotic target PUMA in MSI colorectal cancer (CRC) cells. p53 or PUMA deletion abolished apoptosis induced by WRN depletion in MSI CRC cells. Importantly, correction of MSI abrogated the activation of p53/PUMA and cell killing, while induction of MSI led to sensitivity in isogenic CRC cells. Rare p53-mutant MSI CRC cells are resistant to WRN depletion due to lack of PUMA induction, which could be restored by wildtype (WT) p53 knock in or reconstitution. WRN depletion or treatment with the RecQ helicase inhibitor ML216 suppressed in vitro and in vivo growth of MSI CRCs in a p53/PUMA-dependent manner. ML216 treatment was efficacious in MSI CRC patient-derived xenografts. Interestingly, p53 gene remains WT in the majority of MSI CRCs. These results indicate a critical role of p53/PUMA-mediated apoptosis in the vulnerability of MSI CRCs to WRN loss, and support WRN as a promising therapeutic target in p53 -WT MSI CRCs. |
